ADC Development Services Targeting CD79B

Antibody-drug conjugates (ADCs) represent a promising and effective therapeutic strategy for the clinical management of cancer. Several approved ADCs highlight the potential of ADCs to serve as a new therapeutic option for patients. As the leading service provider in the field of drug discovery, Creative Biolabs offers comprehensive antibody-drug conjugate (ADC) discovery and development services targeting CD79B for customers all over the world.

Introduction of CD79B

CD79B (Cluster of differentiation 79B) is known as immunoglobulin-associated β, which is a B lymphocyte antigen receptor. It is a multimeric complex composed of the antigen-specific component and surface immunoglobulin (Ig). Surface Ig consists of Ig-alpha and Ig-beta (CD79a and CD79b) via the non-covalently connection. The surface Ig units are essential for the expression and function of the B-cell antigen receptor. The functions of the heterodimer include triggering the apoptosis mediated by the BCR, regulating the Ag internalization and increasing the efficiency of Ag presentation. Besides, CD79B is also involved in several pathways such as the B cell receptor signaling pathway, which plays a critical role in protein binding and transmembrane signaling receptor activity.

Fig.1 The B-cell receptor includes both CD79 and the immunoglobulin.

Anti-CD79B ADC for Non-Hodgkin Lymphoma (NHL)

NHL is one of the most common lymphomas in the world, which is a type of cancer that affects the lymphatic system. Traditional therapy strategies such as the chemotherapy and stem-cell transplantation still remain poor outcome, thus, novel therapy methods are needed.

The overexpression of CD79B is found in NHL cells, which can service as the target for novel targeted therapy, such as ADCs. Anti-CD79B ADCs have great potential to improve the therapeutic effect for the NHL. For example, Polatuzumab vedotin (RG7596 or DCDS4501A) is composed of an anti-CD79B monoclonal antibody and the microtubule-disrupting agent monomethyl auristatin E (MMAE) conjugated through a cleavable linker. Its preclinical data have shown significant antitumor activity. In addition, clinical trials also demonstrated that polatuzumab vedotin has an acceptable safety and tolerability profile in patients with NHL.

Fig.2 Polatuzumab Vedotin (Anti-Cd79b ADC). (Advani, 2015)

What Can We Do for You?

With our proprietary quality management system as a foundation, along with our state of the art equipment and facilities, Creative Biolabs strives to provide clients the highest quality ADCs design and construction service against the CD79B. Our ADC Antibody Screening services utilize various advanced technologies to create therapeutic antibody candidates. DrugLnk™ Custom Synthesis services provide customers high-quality linkers or linker-payloads. Antibody Design and Conjugation services aim to achieve effective antibody-payload conjugation. Furthermore, we also provide a comprehensive set of ADC analysis services including the ADC in vitro Analysis and ADC in vivo Analysis. Relying on our extensive experience and advanced equipment, Creative Biolabs offers high-quality service in accordance with your specific needs. If you are interested in our service, please do not hesitate to contact us for more details.

Reference

1. Advani, R. H.; et al. Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level. 2015.

For Research Use Only. NOT FOR CLINICAL USE.